ReShape Lifesciences Announces Public Offering Pricing

The latest announcement is out from ReShape Lifesciences ( (RSLS) ).

On May 30, 2025, ReShape Lifesciences Inc. entered into an Equity Distribution Agreement with Maxim Group LLC to facilitate an at-the-market public offering of up to $9.7 million in common stock. By June 9, 2025, the company announced the pricing of a public offering of 1,054,604 shares at $2.50 per share, expecting gross proceeds of $2,636,510. The proceeds will reduce the maximum available amount under the ATM Offering to $3,420,926, impacting the company’s financial strategy and market operations.

Spark’s Take on RSLS Stock

According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.

ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.

To see Spark’s full report on RSLS stock, click here.

More about ReShape Lifesciences

ReShape Lifesciences Inc. operates in the medical device industry, focusing on developing and commercializing innovative technologies for weight loss and metabolic health.

Average Trading Volume: 1,639,714

Technical Sentiment Signal: Sell

Current Market Cap: $3.09M

For detailed information about RSLS stock, go to TipRanks’ Stock Analysis page.